Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors
Status:
Recruiting
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
Subjects treated with Canagliflozin, Dapagliflozin and Empagliflozin obtained improvement on
blood pressure values, body weight and cardiovascular mortality but pathophysiological
explanations of these effects are not yet known.